Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study

RADAR-CNS consortium

doi:10.1007/s10072-020-04519-x

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study

RADAR-CNS consortium

Afdeling for Hjerne- og Nervesygdomme

42 Citationer (Scopus)

Abstract

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

Originalsprog	Engelsk
Tidsskrift	Neurological Sciences
Vol/bind	41
Udgave nummer	7
Sider (fra-til)	1647-1650
Antal sider	4
ISSN	1590-1874
DOI	https://doi.org/10.1007/s10072-020-04519-x
Status	Udgivet - jul. 2020

Adgang til dokumentet

10.1007/s10072-020-04519-x

Citationsformater

@article{6f1fd2d787584d12865ee4cfc745693e,

title = "Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study",

abstract = "We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.",

keywords = "Adult, Alemtuzumab/therapeutic use, Betacoronavirus, COVID-19, Coronavirus Infections/drug therapy, Europe, Female, Humans, Longitudinal Studies, Male, Middle Aged, Multiple Sclerosis/complications, Pandemics, Pneumonia, Viral/drug therapy, Prevalence, SARS-CoV-2",

author = "{Dalla Costa}, Gloria and Letizia Leocani and Xavier Montalban and Guerrero, {Ana Isabel} and S{\o}rensen, {Per Soelberg} and Melinda Magyari and Dobson, {Richard J B} and Nicholas Cummins and Narayan, {Vaibhav A} and Matthew Hotopf and Giancarlo Comi and {RADAR-CNS consortium}",

year = "2020",

month = jul,

doi = "10.1007/s10072-020-04519-x",

language = "English",

volume = "41",

pages = "1647--1650",

journal = "Neurological Sciences",

issn = "1590-1874",

publisher = "Springer Italia Srl",

number = "7",

}

TY - JOUR

T1 - Real-time assessment of COVID-19 prevalence among multiple sclerosis patients

T2 - a multicenter European study

AU - Dalla Costa, Gloria

AU - Leocani, Letizia

AU - Montalban, Xavier

AU - Guerrero, Ana Isabel

AU - Sørensen, Per Soelberg

AU - Magyari, Melinda

AU - Dobson, Richard J B

AU - Cummins, Nicholas

AU - Narayan, Vaibhav A

AU - Hotopf, Matthew

AU - Comi, Giancarlo

AU - RADAR-CNS consortium

PY - 2020/7

Y1 - 2020/7

N2 - We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

AB - We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

KW - Adult

KW - Alemtuzumab/therapeutic use

KW - Betacoronavirus

KW - COVID-19

KW - Coronavirus Infections/drug therapy

KW - Europe

KW - Female

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis/complications

KW - Pandemics

KW - Pneumonia, Viral/drug therapy

KW - Prevalence

KW - SARS-CoV-2

U2 - 10.1007/s10072-020-04519-x

DO - 10.1007/s10072-020-04519-x

M3 - Journal article

C2 - 32617741

SN - 1590-1874

VL - 41

SP - 1647

EP - 1650

JO - Neurological Sciences

JF - Neurological Sciences

IS - 7

ER -

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater